This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Gene-Editing for High Cholesterol...
Tech Medical breakthrough

Gene-Editing for High Cholesterol Breakthrough

Analysis based on 18 articles · First reported Feb 11, 2026 · Last updated Feb 11, 2026

Sentiment
70
Attention
6
Articles
18
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The gene-editing breakthroughs by CRISPR Therapeutics and Verve PCSK9-inhibitor gene therapy (a subsidiary of Eli Lilly and Company) could revolutionize cardiovascular disease treatment, potentially creating a one-time fix for high cholesterol. This development is highly positive for the biotechnology and pharmaceutical sectors, offering new avenues for growth and significantly impacting the market for existing cholesterol-lowering drugs.

Biotechnology Pharmaceuticals Healthcare
Event Summary

Scientists are developing a new gene-editing treatment for high cholesterol, aiming for a one-time fix for heart disease. Early-stage research by CRISPR Therapeutics and Verve PCSK9-inhibitor gene therapy (a subsidiary of Eli Lilly and Company) shows promising results in lowering artery-clogging cholesterol by switching off specific genes like ANGPTL3 and PCSK9. While these approaches offer hope for preventing heart attacks without lifelong medication, long-term safety studies are still needed. Researchers like Kiran Musunuru, Luke Laffin, and Steven Nissen are at the forefront of this research, with concerns about long-term safety raised by Joseph Wu. The American Heart Association continues to emphasize lifestyle factors for heart health.

Key Actions
95 CRISPR Therapeutics developed gene-editing treatment for high cholesterol
90 Verve PCSK9-inhibitor gene therapy developed PCSK9-targeted gene-editing infusion
85 Eli Lilly and Company supported gene-editing research through subsidiary Verve PCSK9-inhibitor gene therapy
70 Kiran Musunuru co-founded Verve PCSK9-inhibitor gene therapy Verve PCSK9-inhibitor gene therapy
60 Luke Laffin co-authored promising study on ANGPTL3 gene-editing
60 Steven Nissen oversaw ANGPTL3 study funded by CRISPR Therapeutics CRISPR Therapeutics
Entities Involved
stock
CRISPR Therapeutics
CRISPR Therapeutics is developing a gene-editing approach targeting the ANGPTL3 gene, which has shown promising results in early-stage trials by significantly lowering LDL and triglyceride levels. This could lead to a permanent solution for high cholesterol.
Importance 90 Sentiment 75
stock
Eli Lilly and Company
Eli Lilly and Company, through its subsidiary Verve PCSK9-inhibitor gene therapy, is developing a PCSK9-targeted gene-editing infusion that has also shown significant reductions in LDL cholesterol. This positions Eli Lilly and Company as a key player in the gene-editing space for cardiovascular health.
Importance 85 Sentiment 70
stock
Verve PCSK9-inhibitor gene therapy
Verve PCSK9-inhibitor gene therapy, a subsidiary of Eli Lilly and Company, is pioneering a PCSK9-targeted gene-editing infusion that has demonstrated a similar reduction in LDL cholesterol in small studies. Its co-founder, Kiran Musunuru, notes the edits have lasted a lifetime in mice.
Importance 85 Sentiment 70
per
Kiran Musunuru
Kiran Musunuru, a cardiologist at the University of Pennsylvania and co-founder of Verve PCSK9-inhibitor gene therapy, reported on the ANGPTL3 gene mutation and is a key figure in the development and tracking of gene-editing therapies for cholesterol.
Importance 70 Sentiment 60
per
Luke Laffin
Luke Laffin, a preventive cardiologist at the Cleveland Clinic, co-authored a promising study on the ANGPTL3 gene-editing approach funded by CRISPR Therapeutics, highlighting the potential for a one-time fix for high cholesterol.
Importance 60 Sentiment 50
per
Steven Nissen
Steven Nissen, from the Cleveland Clinic, oversaw the ANGPTL3 study funded by CRISPR Therapeutics, which reported significant reductions in LDL and triglyceride levels, contributing to the advancement of gene-editing treatments.
Importance 60 Sentiment 50
per
Joseph Wu
Joseph Wu of Stanford University raises important safety questions regarding CRISPR-based therapies, emphasizing the need for longer studies to understand long-term safety and potential side effects like liver irritation.
Importance 30 Sentiment 0
+ 7 more entities View on Dashboard
Relationships
Verve PCSK9-inhibitor gene therapy related ↔ Eli Lilly and Company
Kiran Musunuru related ↔ Verve PCSK9-inhibitor gene therapy
Luke Laffin related ↔ Cleveland Clinic
Steven Nissen related ↔ Cleveland Clinic
Kiran Musunuru related ↔ University of Pennsylvania
Joseph Wu related ↔ Stanford University
CRISPR Therapeutics related ↔ Eli Lilly and Company
CRISPR Therapeutics related ↔ Verve PCSK9-inhibitor gene therapy
Kiran Musunuru related ↔ CRISPR Therapeutics
Kiran Musunuru related ↔ Eli Lilly and Company
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.